Interview Of Biovista’s President Aris Persidis in Voice Of America by Jessica Berman; Monday, December 10, 2013 Here is an excerpt… “It is a very easy way to explore whether something that is therapeutically beneficial in one area and for one type of patient might be useful for another type of patient,” said Aris … Read More
Year: 2013
Repositioning Gains Momentum in Biopharma Partnerships
Article by Marie Powers in BioWorld; Monday, June 10, 2013 Article summary: Chronic fatigue syndrome (CFS) has been at the center of a vortex of controversy since the FDA handed down a complete response letter on the Toll-like receptor 3 modulator Ampligen (rintatolimod) from Hemispherx Bioscience Inc. – the only drug in development for CFS … Read More
Biovista President to present at the NYBA 2013 Annual Meeting
Biovista President Dr. Aris Persidis will be presenting at the New York Biotechnology Association 2013 Annual meeting. Dr Persidis will be presenting at the “Patient Perspectives: Seeking Cures, Not Just Returns” session and discuss Biovista’s work to date with Patient Advocacy Groups. According to the organizers “patient groups and disease foundations, no longer content to … Read More
GEN: Seasoned Drugs Offer Therapeutic Gold Mine
Article by Caitlin Smith GEN: Genetic Engineering & Biotechnology, May 15, 2013 … Biovista has already repositioned two drugs for the progressive form of multiple sclerosis (MS), which has had few treatment options. Most MS drugs, for treatment of the relapsing-remitting form of MS, compromise the patients’ immune systems and have significant side effects. Biovista … Read More
VA BIOTECH – Concept to Commercialization
Biovista announces that its President, Dr. Aris Persidis, will participate in the “VA BIOTECH – Concept to Commercialization” Facebook event. About VA BIOTECH – Concept to Commercialization event: Charlottesville is home to some of the most cutting edge biotechnology firms in the Country. This panel, presented in partnership with U.Va. Innovation and Charlottesville Business Innovation … Read More